Currently Head of Clinical Pharmacology in UCB, in the past 25 years I covered different roles in various pharmaceutical industries, including GlaxoSmithKline, Rottapharm, Zambon and Pharmacia-Upjohn. My recent experience was mainly dedicated to CNS drug development fo…more ›

Dr. Richard Buller is the Vice President of Translational Oncology in the Pfizer Oncology Business Unit. His group is responsible for development of biomarker and companion diagnostic clinical strategies as well as proof of mechanism/pharmacology for drug candidates. …more ›

Rolf Burghaus started his scientific education at the Heinrich-Heine University of Düsseldorf in 1990 taking courses in mathematics and physics. He soon specialized in theoretical physics where he got his diploma in late 1995. He continued in the field and got his …more ›

- I have an MSc in Mathematics from the University of Liege, Belgium, and a Masters in Biostatistics from the University of Hasselt, Belgium - I have been working as a statistician at Novartis since 2006, where I first supported phase III and IV trials. I am currently w…more ›

Borje Darpo is board-certified in cardiology and internal medicine. He has over 12 years of pharmaceutical industry experience, including senior management positions in small, mid-sized and large pharma, as well as in a global CRO. He has led or has been responsible for…more ›

Antoine Deslandes graduated in Pharmacy and received his Doctorate in Experimental and Clinical Pharmacology from the University of Paris. He joined Servier as preclinical studies manager in Psychiatry/Neurology. He then held different positions in Discovery DMPK at Par…more ›

Dr. Eichenbaum joined Johnson & Johnson Pharmaceutical R&D, LLC (J&J) in 2002. He is a Preclinical Development Leader/Research Fellow in the department of Drug Safety Sciences. He serves on cross-functional compound development teams and is responsible for…more ›

David P. Elder has thirty four years experience within the Pharmaceutical Industry. He is currently a director at GlaxoSmithKline Pharmaceuticals. He obtained a part-time PhD from Edinburgh University in1992 investigating the crystal structure and solid-state chemistr…more ›

Marten Heeringa PhD is clinical pharmacologist by training and currently Associate Scientific Director at Astellas Pharma. In this capacity, he is responsible for creating global clinical pharmacology and exploratory development strategies, with emphasis on translationa

Dr. Tycho Heimbach is an Associate Director at Novartis Institutes for BioMedical Research in East Hanover, NJ. In his current role, he chairs a global team which reviews and makes recommendations for formulation and PK/PD strategies for all disease areas within the gl…more ›

Thierry Lavé is Head of Modeling and Simulation, Non Clinical Safety, Hoffmann-La Roche. He received his degree in Pharmacy (1987) and Ph.D. (1992) from the Strasbourg University, France. Thierry has also 5 year of experience working as Internist at the University…more ›

Dr. Michael Merz is a clinical pharmacologist by training, with a focus on drug safety testing during the past couple of years. He worked as phase 1 investigator and Head of Phase 1 clinic for Quintiles in Freiburg, Germany, from 1993 to 1997 and joined Novartis Pharma …more ›

2005 Board certification as Clinical Pharmacologist Professional Experience (incl. Memberships) 1992 - 1993 Internship (Internal Medicine) 1993 - 1995 Scientist, Clinical Pharmacology, University of Rostock 1995 - 2001 Scientist, Clinical Pharmacology, Schering AG, Be…more ›

Dr Elizabeth Foot is Chief Executive Officer for London Genetics International, a specialist company created to facilitate partnerships between industry and academic centres of excellence in genetics and the field of stratified medicine. She has extensive experience of